Page 76 - Fisica In Medicina n° 1/2017

^Äëíê~Åí=jÉÇáÅá= =Phase II trial on SBRT for unresectable Liver Metastases: Long-term outcomes and prognostic factors of survivalT. COMITO1, C. FRANZESE1, E. CLERICI1, A. TOZZI1, C. IFTODE1, P. NAVARRIA1, G. D’AGOSTINO1, F. DE ROSE1, D. FRANCESCHINI1, AM. ASCOLESE1, L. DI BRINA1, M. SCORSETTI11: Radioterapia, Humanitas Research and Clinical HospitalIntroductionThe aim of this study was to evaluate long-term efficacy and survival prognostic factors of SBRT for unresectable liver metastases.Methods and Materials5 years local control (LC), overall survival (OS), progression free survival (PFS) and toxicity rates were analyzed in patients with unresectable liver metastases enrolled in a Phase II Trial on liver SBRT, with a prescription dose of 75 Gy on 3 consecutive fractions.ResultsBetween February 2010 and September 2011, a total of 61 patients with 76 lesions were enrolled in this prospective trial, with a median follow-up time of 1.9 years. One-, three- and five- years LC rates were 94%, 78% and 78 %, respectively, with a median LC of 1.7 years. Median OS was 2.3 years and the survival rates were 83%, 30% and 21% at 1, 3 and 5 years, respectively. Univariate analysis showed two independent positive prognostic factors affecting survival: female sex (p = 0.012) and primary tumour (p = 0.001). Toxicity was moderate. One patient experienced G3 late chest wall pain, which resolved within 1 year from SBRT. No cases of RILD were detected.ConclusionsLong-term results of this Phase II study suggest the efficacy and safety of SBRT for unresectable liver metastases also at 5 years of follow-up. Selection of cases with positive prognostic factors may improve long-term survival of these oligometastastic patients and may confirm the role of SBRT as an effective alternative local therapy for liver metastases.67